Bausch & Lomb
This article was originally published in The Gray Sheet
U.S. approval for the Keracor 116 excimer laser system for photorefractive keratectomy is announced Oct. 4. However, the company will forgo marketing and instead devote resources to the Technolas 217 for laser in situ keratomileusis, for which approval is anticipated by year-end. The Keracor 116 is indicated for correction of myopia of -1.5 to -7.0 diopters with up to -4.5 D of astigmatism. The device's use "will be limited to the investigational device exemption users originally recruited to perform the clinical studies," B&L says
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.